Page 5 - Billy Cho News Today : Breaking News, Live Updates & Top Stories | Vimarsana

[December 28, 2020] Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China's National Reimbursement Drug List SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has been included in the updated National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA). ZEJULA (niraparib) is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor with national Category 1 designation. It has been...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for ... Zai Lab LimitedDecember 28, 2020 GMT - Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties - Zai Lab to join ongoing global trial for CLN-081 SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative co...